Atazanavir en el tratamiento de simplificación | Enfermedades Infecciosas y Microbiología Clínica

ISSN: 0213-005X

Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.

Ver más Opción Open Access

Indexada en:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS

Atazanavir es un nuevo inhibidor de la proteasa azapéptido con un perfil farmacocinético singular, que permite la administración una vez al día de sólo 2 cápsulas en combinación con otros antirretrovirales. Su potente eficacia antiviral se acompaña, además, de un perfil de tolerancia excelente y de ausencia de incrementos significativos de las concentraciones de colesterol y triglicéridos. La respuesta inmunológica y virológica obtenida con atazanavir o atazanavir/ritonavir, tanto en pacientes naive como en pacientes con fracaso virológico previo a otros inhibidores de la proteasa, es excelente. Atazanavir es un atractivo fármaco para la simplificación terapéutica. Además de mantener la supresión virológica, los pacientes que cambian de otros inhibidores de la proteasa a atazanavir presentan reducciones en el colesterol total, el colesterol unido a lipoproteínas de alta densidad (cHDL) y los triglicéridos. Datos preliminares indican también que el tratamiento de mantenimiento simplificado con atazanavir/ritonavir en monoterapia puede mantener la supresión virológica de manera eficaz en pacientes seleccionados.

Palabras clave:

Atazanavir

Inhibidores de la proteasa

Simplificación

Tratamiento de mantenimiento

Tratamiento de rescate

Atazanavir is a new azapeptide protease inhibitor with a remarkable pharmacokinetic profile, which means it can be administered in only two capsules once per day in combination with other antiretrovirals. Its strong antiviral efficacy is also accompanied by an excellent tolerance profile and no significant increase in cholesterol and triglyceride levels. The immunological and virological response obtained with atazanavir or atazanavir/ritonavir, in naive patients as well as in patients with previous virological failure with other protease inhibitors, is excellent. Atazanavir is an attractive drug for therapeutic simplification. Besides maintaining virological suppression, patients who change from other PI to atazanavir experience reductions in total cholesterol, HDL cholesterol and triglycerides. Preliminary data suggest that simplified maintenance treatment with atazanavir/ritonavir in monotherapy, can effectively maintain virological suppression in selected patients.

Key words:

Atazanavir (ATV)

Protease inhibitor (PI)

Simplification

Maintenance treatment

Rescue treatment

El Texto completo está disponible en PDF

Bibliografía

[1.]

D.V. Havlir, S.D. O’Marro.

Atazanavir: new option for treatment of HIV infection.

Clin Infect Dis, 38 (2004), pp. 1599-1604

http://dx.doi.org/10.1086/420932 | Medline

[2.]

D.R. Goldsmith, C.M. Perry.

Atazanavir.

Drugs, 63 (2003), pp. 1679-1693

Medline

[3.]

J. Mensa, J.M. Gatell, M.T. Jimenez de Anta.

Guía de terapéutica antimicrobiana.

Masson, (2006),

[4.]

S. Mauss, F. Berger, G. Schmutz, W.O. Richter.

Atazanavir does not seem to have lipid lowering properties in patients with contolled HIV infection and normal lipids.

XV International Conference on AIDS,

[5.]

S.T. Nguyen, S.A. Eaton, A.M. Bain, A.P. Rahman, K.D. Payne, R. Bedimo, et al.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavirbased highly active antiretroviral therapy in patients with human immunodeficiency virus.

Pharmacotherapy, 28 (2008), pp. 323-330

http://dx.doi.org/10.1592/phco.28.3.323 | Medline

[6.]

M. Colafigli, S. Di Giambenedetto, L. Bracciale, E. Tamburrini, R. Cauda, A. De Luca.

Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.

HIV Med, 9 (2008), pp. 172-179

http://dx.doi.org/10.1111/j.1468-1293.2007.00541.x | Medline

[7.]

G. Thal, M. Maa, L. McManus, L. Bessen, L. Abrams, E. Cooney.

Improvement in hyperlipidemia following switch of antiretroviral therapy to an atazanavir- based HAART regimen: experience from the US atazanavir early access program.

15th International AIDS Conference,

[8.]

I. Sanne, P. Piliero, K. Squires, A. Thiry, S. Schnittman.

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

J Acquir Immune Defic Syndr, 32 (2003), pp. 18-29

Medline

[9.]

R.L. Murphy, I. Sanne, P. Cahn, P. Phanuphak, L. Percival, T. Kelleher, et al.

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

AIDS, 17 (2003), pp. 2603-2614

http://dx.doi.org/10.1097/01.aids.0000096930.51231.5d | Medline

[10.]

K. Squires, A. Lazzarin, J.M. Gatell, W.G. Powderly, V. Pokrovskiy, J.F. Delfraissy, et al.

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

J Acquir Immune Defic Syndr, 36 (2004), pp. 1011-1019

Medline

[11.]

R.J. Colonno, A. Thiry, K. Limoli, N. Parkin.

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.

Antimicrob Agents Chemother, 47 (2003), pp. 1324-1333

Medline

[12.]

P. Sista, B. Wasikowski, P. Lecocq, T. Pattery, L. Bacheler.

The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.

J Clin Virol, 42 (2008), pp. 405-408

http://dx.doi.org/10.1016/j.jcv.2008.03.023 | Medline

[13.]

D.R. Malan, E. Krantz, N. David, V. Wirtz, J. Hammond, D. McGrath.

Efficacy and safety of atazanavir, with or without ritonavir, as part ofonce-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

J Acquir Immune Defic Syndr, 47 (2008), pp. 161-167

http://dx.doi.org/10.1097/QAI.0b013e31815ace6a | Medline

[14.]

K.Y. Smith, W.G. Weinberg, E. Dejesus, M.A. Fischl, Q. Liao, L.L. Ross, et al.

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plustenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-weekresults of ALERT.

AIDS Res Ther, 5 (2008), pp. 5

http://dx.doi.org/10.1186/1742-6405-5-5 | Medline

[15.]

R. Elion, E. Dejesus, M. Sension, D. Berger, W. Towner, G. Richmond, et al.

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study.

HIV Clin Trials, 9 (2008), pp. 152-163

http://dx.doi.org/10.1310/hct0903-152 | Medline

[16.]

Molina JMl, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabinein ARV-naive HIV-1-infected subjects: the CASTLE Study, 48-week results. Boston: 15th CROI; 2008.

[17.]

M. Johnson, B. Grinsztejn, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, et al.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

AIDS, 19 (2005), pp. 153-162

Medline

[18.]

M. Jhonson, B. Ginsztejn, C. Rodríguez, J. Coco, E. DeJesus, A. Lazzarin, et al.

96-week comparison of once-daily atazanavir/ritonavir and lopinavir/ritonavir in patients with multiple virologic failures.

AIDS, 20 (2006), pp. 711-718

http://dx.doi.org/10.1097/01.aids.0000216371.76689.63 | Medline

[19.]

L. Cuzin, P. Flandre, P. Pugliese, C. Duvivier, Y. Yazdanpanah, E. Billaud, et al.

Atazanavir in patients with persistent viral replication despite HAART: results from the French Prospective NADIS Cohort.

HIV Clin Trials, 9 (2008), pp. 147-151

http://dx.doi.org/10.1310/hct0903-147 | Medline

[20.]

R. Wood, P. Phanuphak, P. Cahn, V. Pokrovskiy, W. Rozenbaum, G. Pantaleo, et al.

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. AI424- 044.

J Acquir Immune Defic Syndr, 36 (2004), pp. 684-692

Medline

[21.]

J. Gatell, D. Salmon-Ceron, A. Lazzarin, E. Van Wijngaerden, F. Antunes, C. Leen, et al.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Clin Infect Dis, 44 (2007), pp. 1484-1492

[22.]

V. Soriano, P. Garcia-Gasco, E. Vispo, A. Ruiz-Sancho, F. Blanco, L. Martin-Carbonero, et al.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

J Antimicrob Chemother, 61 (2008), pp. 200-205

http://dx.doi.org/10.1093/jac/dkm413 | Medline

[23.]

S. Rodriguez-Novoa, J. Morello, P. Barreiro, I. Maida, P. Garcia-Gasción, E. Vispo, et al.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

AIDS Res Hum Retroviruses, 24 (2008), pp. 821-825

http://dx.doi.org/10.1089/aid.2007.0276 | Medline

[24.]

P. Vernazza, S. Daneel, V. Schiffer, L. Decosterd, W. Fierz, T. Klimkait, et al.

The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.

AIDS, 21 (2007), pp. 1309-1315

[25.]

S. Sahali, M.L. Chaix, J.F. Delfraissy, J. Ghosn.

Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

AIDS Rev, 10 (2008), pp. 4-14

Medline

[26.]

J. Mallolas, D. Podzamczer, P. Domingo, B. Clotet, E. Ribera, F. Gutierrez, et al.

Efficacy and safety of switching from lopinavir/ to atazanavir/r in patients with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study.

4th IAS Conference HIV Patohogenesis, Treatment and Prevention,

[27.]

J. Mallolas, D. Podzamczer, P. Domingo, B. Clotet, E. Ribera, F. Gutierrez, et al.

Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression and history of previous PI failures or PI resistance mutations: Subanalysis of the ATAZIP study.

EACS meeting,

[28.]

S. Swindells, G. DiRienzo, Wilkin, C.V. Fletcher, D.M. Margolis, G.D. Thal, et al.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

JAMA, 296 (2006), pp. 808-814

[29.]

M.J. Perez-Elias, J.M. Gatell, J. Flores, J. Santos, F.J. Vera, B. Clotet, et al.

Effect of ritonavir-boosted atazanavir (ATV/r) in experienced HIV-infected patients regarding hepatitis B/C status.

3rd International AIDS Conference,

[30.]

J.A. Pineda, R. Palacios, A. Rivero, L. Abdel-kader, M. Márquez, P. Cano, et al.

Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.

J Antimicrob Chemother, 57 (2006), pp. 1016-1017

[31.]

J.A. Pineda, J. Santos, A. Rivero, L. Abdel-Kader, R. Palacios, A. Camacho, et al.

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.

J Antimicrob Chemother, 61 (2008), pp. 925-932

http://dx.doi.org/10.1093/jac/dkn045 | Medline

[32.]

C. Couzigou, M. Daudon, J.L. Meynard, F. Borsa-Lebas, D. Higueret, L. Escaut, et al.

Urolithiasis in HIV-positive patients treated with atazanavir.

Clin Infect Dis, 45 (2007), pp. e105-e108

http://dx.doi.org/10.1086/521930 | Medline

Publique en

Enfermedades Infecciosas y Microbiología Clínica

Herramientas

Artículos
recomendados

Synergic effect of metabolic syndrome and lipodystrophy on...

Enferm Infecc Microbiol Clin. 2022;40:310-6

La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica agradece la colaboración de:

SOCIOS PROTECTORES

SOCIOS PATROCINADORES

- Becton Dickinson S.A.U.
- Janssen-Cilag, S.A.
- Angelini Farmacéutica, S.A.
- Biomerieux España, S,A.U.
- Merck Sharp & Dohme de España, S.A.
- Hologic Iberia, S.L.U.
- Laboratorios Menarini S.A.
- Accelerate Diagnostics S.L.
- Abbott Laboratories, S.A.
- Cepheid Iberia S.L.U.
- Illumina Productos de España. S.L.U.
- DiaSorin Iberia, S.A.
- GlaxoSmithKline, S.A.
- Sysmex España S.L.

Enfermedades Infecciosas y Microbiología Clínica sigue las recomendaciones para la preparación, presentación y publicación de trabajos académicos en revistas biomédicas

Descargar PDF

Indexada en:

Síguenos:

Suscribirse:

Indexada en:

Síguenos:

Suscribirse:

Suscríbase a la newsletter